WHO Medicines Access Platform ‘Compromised’ By Industry Involvement
A new World Health Organization platform for discussing access to medicines could be too heavily influenced by the pharmaceutical industry, says the NGO Health Action International. The European industry federation EFPIA disagrees.
You may also be interested in...
Delegates at the European Health Forum Gastein outlined the challenges facing an international effort to improve access to costly new medicines across the World Health Organization’s European region, insisting that the key issues had to be addressed “collectively” and without “finger pointing.”
New platform for finding solutions to increase access to expensive medicines should ensure sustainability of health care systems and pharmaceutical industry and could include tiered pricing models.
The Scottish health technology appraisal body, the SMC, has announced its recommendations on Sanofi’s Dupixent, Ipsen’s Cabometyx, Sobi’s Zynlonta and Novartis’ Cosentyx.